syphilis reagin, but it is felt that administration of penicillin probably has the effect of increasing the Kahn titre during the first week of treatment in patients with early syphilis. Following completion of treatment, Kahn tests are being taken at weekly intervals on all patients. In five patients who had a positive STS at the beginning of treatment, and who have now been followed for five weeks, the STS has become negative. This is in accord with Mahoney's observation in four patients, that the STS became negative in from four to seven weeks after administration of 1,280,000 units of penicillin over a period of eight and one-half days.
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SUMMARY
Penicillin has a strikingly beneficial effect in the treatment of early syphilis. In our small series, the rate of disappearance of spirochetes and the healing of early lesions were both more rapid than that observed after ars.phenamine therapy, either of the conservative or intensive type. The absence of reactions to treatment, and the short time during which treatment may be compressed, make this method of treatment of great potential value in military medicine. Prolonged arsphenamine bismuth therapy for syphilis is unsatisfactory at best, and under conditions of war the difficulties of carrying it out regularly may at times be insurmountable. Intensive therapy offers the advantage of assuring the patient of completion of treatment and prospect of cure in 85 to 90 per cent. of patients, but requires hospitalization for twenty to twenty-five days, and must be given under expert direction if undue reactions to treatment are to be avoided. The lmmediate effects of penicillin are greatly superior, and it is hoped that the initial promise of this method will be con rined by the extensive studies now proceeding in the United States and elsewhere. THE antibacterial drugs of the sulphanilyl grouip, beginning with prontosil and sulphanilamide, were evolved without knowledge of the target to be attacked within the disease-producing bacteria. But the introduction of these drugs took place at a time when great advances had been made in our knowledge of bacterial biochemistry. A turning point came when it was shown by Woods (1940) that p-aminobenzoic acid was a specific antagonist of bacterial growth-inhibitions caused by sulphanilamide. This observation directly linked the growth-inhibitory etfects of the antibacterial drug with the growth processes of the bacterial parasite in a way which threw unexpected light on the target in the parasite at which the drug should be aimed-namely its metabolic processes. The chemical relation between the drug sulphanilamide, i.e. p-aminobenzene sulphonamide and its natural antagonist p-aminobenzoic acid, is very striking, the drug having a sulphonamide group in place of the carboxyl group of its antagonist. Woods suggested that p-aminobenzoic acid itself was really an important metabolite for the streptococci with which he was working, and that it was the normal utilization of this essential metabolite with which the sulphanilamide interfered. Soon after, p-aminobenzoic acid was indeed found to be an essential growth factor for several different species of bacteria, as-Woods had predicted (Rubbo and Gillespie, 1940; Lampen and Peterson, 1941; Lampen, Underkofler and Peterson, 1942) . This substance'is now recognized as an essential metabolite for many bacterial species as well as for other types of organism. Woods showed that the relation of sulphanilamide to p-aminobenzoic acid in his case was analogous to that found in the competitive inhibition. of an enzyme reaction. This suggested that the sulphanilamide competed with p-aminobenzoic acid in the utilization of the latter by an enzyme system of the bacterial cell for which p-aminobenzoic acid was the normal,substrate, this enzyme reaction being essential for the growth of the bacterial cell.
The generalization which followed from this was put forward by Fildes (1940) namely, that bacteriostatic substances could be designed deliberately to interfere with' metabolic reactions which were essential to the growth of the bacteria it was desired to inhibit, by making the inhibitor to have a chemical structure related to, but sufficiently different from, one of the essential metabolites of the cell. The drug might then be expected to interfere with the use of the normal metabolite, by some form of enzyme inhibition.
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The inhibitory metabolite analogue should have a structure resembling the natural metabolite so closely that it would have very similar physical constants and thus be an effective competitor in its specific enzyme reaction; and at the same time be sufficiently different chemically for this enzyme reaction to be unable to employ the metabolite analogue effectively. Other ways of inhibiting enzyme reactions are of course possible but cannot be considered here. Two points immediately arise: (a) How to find and choose the required essential metabolite; (b) how to model the chemical structure of the drug so that it shall reach the target and interfere with that vital process in which the chosen essential metabolite is normally used.
There is much evidence which suggests that the substances collectively called growth factors, which have been found to be essential nutrients for one or more species of bacteria, are in fact substances which are essential in the metabolism of a much wider range of organisms. The reason why certain of these substances appear to be essential ntutrients for certain species is that these species are unable to synthesize these substances for themselves. Since they are essential to the metabolism of these species, the substances must be acquired preformed from the nutrient environment, just as the vitamins of animal nutrition must be supplied by the food.
The point that these substances, discovered to be essential nutrients for certain bacteria, are really members of a much wider class of essential metabolites required by a large range of organisms, is emphasized by the observation that, in all these cases where examination has been made, bacteria which do not require to be given one or other of these growth factors as an essential nutrient, do in fact synthesize these substances.
To summarize: The discovery of essential growth factors or essential nutrients is one way for discovering substances which are components of essential metabolic processes. A mere recital of some of the known bacterial growth factors will show that these substances are common to a verv wide range of living organisms. Thus: Aneurin (vitamin B1); riboflavin (vitamin B2): nicotinic acid; pantothenic acid; biotin; p.yridoxin (vitamin BG). Each of these has been found to be an essential nLutrient for certain species of bacteria, yeasts, moulds, and higher animals. In general there is evidence which suggests that there is a biochemistry which is common to widely different forms of living matter, and which is expressed in the use of common metabolic reactions in their life processes.
Thus the whole range of growth factors, of which more are known at present for micro-organisms than for higher animals, can assist in making specific the targets in bacteria and other disease-producing micro-organisms at which drugs can be aimed, since even if we do not know what are the metabolic reactions in which these growth factors take part we at least know that these substances are essential components of these v-ital reactions.
Other sulphanilyl drugs such as sulphapyridine, sulphathiazole, sulphadiazine, sulphaguanidine are all chemical variants of the same fundamental p-aminobenzene sulphonamide structure as in sulphanilamide, and their actions all appear to be directed primarily to interference with the p-aminobenzoic acid enzyme svstem. The bacteriostatic effects of all these sulphanilyl drugs can be abolished by p-aminobenzoic acid. Differences of activity among these related sulphanilyl derivatives appear to be quantitative rather than qualitative. Thev are probably due mainly to the somewhat different physical constants which the variations in chemical structure impart, thus making them more or less similar in effect to the master compound p-aminobenzoic acid, in regard to the molecular forces in play at the enzyme locus where the normal substrate p-aminobenzoic acid would be used.
A number of bacterial growth inhibitors has been prepared following the theory that growth inhibitors can be designed by a reference to the structure of known essential metabolites. Thus, pyridine-3-sulphonic acid or its amide inhibits certain bacteria which require nicotinic acid, i.e. pyridine-3-carboxylic acid, the inhibition being reversed by n:cotinic acid or its amide (Mcllwain, 1940}. Certain bacteria which require pantothenic acid can be inhibited by pantoyltaurine, the sulphonamide analogue of pantothenic acid; this inhibition is reversed by pantothenic acid (Snell, 1941; Mcllwain, 1942; Barnett and Robinson, 1942) . Pyrithiamin, in which the thiazole ring of thiamin (aneurin) is changed for a pyridine ring, showed inhibitory effects whch were reversed by thiamin (aneurin) (Woolley and White, 1943) . One further example is the inhibitory effect of a-amino-sulphonic acid analogues of certain simple a-amino-carboxylic acids (glycine, alanine, etc.) which were required as nutrients by certain bacteria (Mcllwain, 1941) .
Thus there is ito lack of evidence that growth inhibitors can be prepared by modelling them on the known essential metabolites.
EFFECTS DUE TO THE HOST
How effective such compounds might be when used in vivo will depend in the first instance on the usual relation between effect on the parasite and on the host. Because, as is clear, the essential metabolites themselves are, in all the cases mentioned, also essential for the host animal, including man.
Using pantoyltaurine, Mcllwain and Hawking (1943) were able to afford protection to rats against large attacking doses of haemolytic streptococci, but a similar protection could not be afforded to mice. The mice had in their blood a higher concentration of pantothenate (the natural essential metabolite) than had the rats. Injected pantoyltaurine was unable to produce a high enough ratio of pantoyltaurine to pantothenate to bring about bacteriostasis in the mice. In the rat blood, the pantothenate concentration was low enough for injected pantoyltaurine to be able to maintain the pantoyltaurine/pantothenate ratio large enough to produce a bacteriostasis. This ratio agreed with that expected from in vitro experiments. Thus the concentration of a given essential metabolite in the host can effect the result of the use of its corresponding inhibitory analogue against a parasite in that host.
The same drug might thus have apparently different effectiveness against the same parasite in different species of host. But this could also clearly apply to different individuals of the same species, depending on their nutritional conditions. Thus, one human subject, suffering from a nutritional p-aminobenzoic acid deficiency, might show a better response in treatment with sulphathiazole or other sulphanilyl derivative than another human subject who, because of a different diet or for other reasons, had much more free p-aminobenzoate in his tissues or blood, even though the attacking organisms were from the same culture, or showed the same sensitivity in vitro.
Thus in general, individual hosts might show different effects in treatment by the same drug, due to differences in the concentration of the drug's natural antagonist. A natural antagonist will always be present in the host in all the cases where the growth inhibitor is modelled on an essential metabolite.
RELATION OF CHEMICAL STRUCTURES OF METABOLITE AND INHIBITOR
Of the five groups of inhibitors modelled on essential metabolites just mentioned, four of them contain sulphonamide groups in place of a carboxyl group in the natural metabolite. It is clear that this sulphonamide group sufficiently resembles the carboxyl group in its physical constants to be a very close substitute in this respect (cf. Bell and Roblin, 1942; Kumler and Daniels, 1943) . It thus permits effective competition in the enzyme systems which normally use the natural metabolite. Further, this sulphonamide group, in spite of its close resemblance to the carboxyl group, is sufficiently unusual chemically for the enzymes of the cells neither to be able to use it instead of the carboxyl group (because it cannot participate in the normal series of chemical reactions required) nor to be able to split it off easily and thus render the molecule an ineffective competitor. The case of pyrithiamin shows however that the sulphonamide group itself cannot be looked upon as a toxic group of the molecule in the old chemotherapeutic sense since here an inhibitor is modelled without a sulphonamide group. Doubtless inhibitors which might be modelled on other essential metabolites, such as riboflavin or pyridoxin, which do not contain carboxyl groups, might require groups other than sulphonamide groups to enable them to make effective-contact with an appropriate enzyme system while not being chemically usable by it.
DRUG TOLERANCE
An important property of bacterial cells, which can cause difficulties in using drugs which inhibit essential metabolic reactions, is that of metabolic adaptability, which can give rise to drug-resistant strains. The synthetic powers of bacteria are by no means so fixed as they become in higher types of organism which have evolved a well-defined apparatus of genetic control of their biochemical processes. In bacteria the mechanisms that determine how closely daughter-cells shall resemble the parent cell are much less insulated from the environment than these mechanisms become when more evolved and more clearly differentiated. Thus,. phenomena of adaptation in response to environmental conditions are often found with bacteria and this adaptability Section of Mediwine 495. often relates to the cells' powers of synthesis. In regard to a given essential metaboli* some species may be able to synthesize it quite easily. Other species will be unable to synthesize it sufficiently rapidly, and must be given it as a nutrient. Similar differences may occur between different strains of the same species. Merely different rates of synthesis of an essential metabolite could give rise to different results from a drug acting on the different strains, since these strains would be capable of producing the natural antagonist of the drug at different rates.
It is possible to train nutritionally exacting strains of bacteria to become less exactin by becoming faster synthesizers of a metabolite which they ordinarily acquire preformed fromtheir nutrients. One of the ways of doing this is continued sub-culture under sub-optimal nutrient conditions (e.g. Koser and Wright, 1943) . In the case of drug resistance this can be done by sub-culture in somewhat less than bacteriostatic concentrations of the drug (McIlwain, 1943a) . Here the drug, as a metabolite inhibitor, is partially blocking the use ofthe normal metabolite, thus -causing a partial starvation to which the bacterial cell can respond by an increased rate of synthesis of the natural metabolite. This adapted strain will then need higher concentrations of drug to inhibit it. These concentrations may be outside the practical range in treatment. In certain cases it has been shown that bacteria rendered resistant to drugs of the sulphanilyl group did in fact synthesize more p-aminobenzoic acid than did the normal sensitive strains (Landy, Larkum, Oswald and Streightoff 1943; McIlwain 1943a) .
This drug resistance, due to an increased rate of synthesis of the natural drug antagonist (i.e. the normal essential metabolite) once acquired, can persist through subsequent subcultures in varying degrees. To avoid the conditions of exposure to sub-bacteriostatic concentrations of drug which could give rise in this way to drug-tolerant strains, is an important reason for avoiding prolonged treatment with small doses of drug. Once a strain has been made tolerant to one member of the sulphanilyl group, it will be tolerant also to the other members of this group if its tolerance is due to its having acquired a greater power to synthesize p-aminobenzoic acid, or is otherwise related to p-aminobenzoic acid metabolism. Such a strain might then usefully be attacked by an inhibitor modelled on another essential metabolite, such as pantoyltaurine as McIlwain and Hawking suggested, since the strain will not have been trained to synthesize pantothenic acid at an enhanced rate by cultivation in the presence of a p-aminobenzoic acid inhibitor.
Another way in which a drug-tolerant strain might arise is theoretically possible. This is when the bacterial cells respond to the drug, not by an increased production of the corresponding natural metabolite, but by using a new series of metabolite reactions which have the effect of by-passing the reaction stage which the inhibitor is blocking. It must also be remembered that the infecting organisms may not be a nutritionally pure culture, so that selection of a strain best able to cope with the given nutritional environment, which will include the drug, may also occur.
A secondary effect of the use of drugs modelled on essential metabolites is the effect of the drug on the nutrition of the host. Although p-aminobenzoic acid is not yet generally accepted as a vitamin of human nutrition, there is reason to believe that this substance does play a part in human metabolism, so that prolonged use of a drug of the sulphanilyl group might interfere with the p-aminobenzoic acid mechanism of the host.
A further, more general nutritional derangement also could follow from the effect of the drug on the bacterial flora of the intestines. Since it seems probable that the bacteria of the intestines synthesize vitamins which are used in the nutrition of the host, a radical change in this flora produced by drug treatment might result in smaller quantities of vitamins becoming available to the host from this source. The point emerges that the successful chemotherapeutic treatment itself may cause temporary nutritional deficiencies in the host. These could be remedied by suitable vitamin supplements during convalescence.
NATURAL ANTrIBIOTICS
Finally, turning briefly to the naturally occurring antibiotics, of which penicillin is outstanding, there is very little that can be said at present from the point of view of bacterial metabolism. Penicillin is only one case in many, in which a metabolic product of one species of micro-organism is antagonistic to the growth of other species. Numerous other examples of antagonism between bacterial species due to the production of inhibitory substances are known, for example, gramicidin, tyrocidin, and streptothricin. The existence of these substances produced by the flora of the soil opens interesting problems of soil ecology. It would be tempting to see in these substances the evolution of protective substances for the particular species which produce them. But this may be a much too teleological view of the matter. At present there appears to be no evidence connecting the chemical composition ofthese natural antibiotics, where known, with any of the essential metabolites already mentioned, except possibly gramicidin with protein synthesis.
The bacterial pigment iodinin, which is a phenazine derivative, has inhibitory effects against streptococci, the inhibition being reversed by various anthraquinone and naphthaquinone derivatives, including synthetic vitamin K substitutes (Mcllwain, 1943b) . One possible approach to the discovery of the mode of action of natural antibiotics is to seek, in cells which they do not inhibit, possible natural antagonists, which might be expected to be related to the essential reactions with which the antibiotic interfered.
